Sally Shumaker to Middle Aged
This is a "connection" page, showing publications Sally Shumaker has written about Middle Aged.
Connection Strength
0.414
-
Kirk JK, Hunter JC, Mihalko SL, Danhauer SC, Shumaker SA. Perspectives of pain in patients with type 2 diabetes. Expert Rev Endocrinol Metab. 2019 05; 14(3):215-219.
Score: 0.061
-
Mojtabai R, Corey-Lisle PK, Ip EH, Kopeykina I, Haeri S, Cohen LJ, Shumaker S. The Patient Assessment Questionnaire: initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder. Psychiatry Res. 2012 Dec 30; 200(2-3):857-66.
Score: 0.038
-
Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, Shumaker SA. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol. 2009 Nov 01; 27(31):5144-52.
Score: 0.031
-
Naughton MJ, Jones AS, Shumaker SA. When practices, promises, profits, and policies outpace hard evidence: the post-menopausal hormone debate. J Soc Issues. 2005 Mar; 61(1):159-79.
Score: 0.023
-
Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA. Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. Psychosom Med. 2005 Jan-Feb; 67(1):98-104.
Score: 0.023
-
Levine DW, Kaplan RM, Kripke DF, Bowen DJ, Naughton MJ, Shumaker SA. Factor structure and measurement invariance of the Women's Health Initiative Insomnia Rating Scale. Psychol Assess. 2003 Jun; 15(2):123-36.
Score: 0.020
-
Levine DW, Kripke DF, Kaplan RM, Lewis MA, Naughton MJ, Bowen DJ, Shumaker SA. Reliability and validity of the Women's Health Initiative Insomnia Rating Scale. Psychol Assess. 2003 Jun; 15(2):137-48.
Score: 0.020
-
Welti LM, Beavers KM, Mampieri A, Rapp SR, Ip E, Shumaker SA, Beavers DP. Patterns of Home Environmental Modification Use and Functional Health: The Women's Health Initiative. J Gerontol A Biol Sci Med Sci. 2020 10 15; 75(11):2119-2124.
Score: 0.017
-
Gaussoin SA, Espeland MA, Beavers DP, Casanova R, Garcia KR, Snively BM, Shumaker SA, Wallace RB, Rapp SR. Dementia outcomes after addition of proxy-based assessments for deceased or proxy-dependent participants. Int J Geriatr Psychiatry. 2019 10; 34(10):1403-1411.
Score: 0.015
-
Driscoll I, Snively BM, Espeland MA, Shumaker SA, Rapp SR, Goveas JS, Casanova RL, Wactawski-Wende J, Manson JE, Rossom R, Brooks J, Hernandez DG, Singleton AB, Resnick SM. A candidate gene study of risk for dementia in older, postmenopausal women: Results from the Women's Health Initiative Memory Study. Int J Geriatr Psychiatry. 2019 05; 34(5):692-699.
Score: 0.015
-
Breathett K, Leng I, Foraker RE, Abraham WT, Coker L, Whitfield KE, Shumaker S, Manson JE, Eaton CB, Howard BV, Ijioma N, Cené CW, Martin LW, Johnson KC, Klein L. Risk Factor Burden, Heart Failure, and Survival in Women of Different Ethnic Groups: Insights From the Women's Health Initiative. Circ Heart Fail. 2018 05; 11(5):e004642.
Score: 0.014
-
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017 09 12; 318(10):927-938.
Score: 0.014
-
Espeland MA, Rapp SR, Manson JE, Goveas JS, Shumaker SA, Hayden KM, Weitlauf JC, Gaussoin SA, Baker LD, Padula CB, Hou L, Resnick SM. Long-term Effects on Cognitive Trajectories of Postmenopausal Hormone Therapy in Two Age Groups. J Gerontol A Biol Sci Med Sci. 2017 Jun 01; 72(6):838-845.
Score: 0.013
-
Coker LH, Espeland MA, Hogan PE, Resnick SM, Bryan RN, Robinson JG, Goveas JS, Davatzikos C, Kuller LH, Williamson JD, Bushnell CD, Shumaker SA. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies. Neurology. 2014 Feb 04; 82(5):427-34.
Score: 0.011
-
Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013 Aug 12; 173(15):1429-36.
Score: 0.010
-
Vaughan L, Espeland MA, Snively B, Shumaker SA, Rapp SR, Shupe J, Robinson JG, Sarto GE, Resnick SM. The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). Brain Res. 2013 Jun 13; 1514:3-11.
Score: 0.010
-
Espeland MA, Pettinger M, Falkner KL, Shumaker SA, Limacher M, Thomas F, Weaver KE, Stefanick ML, McQuellon C, Hunt JR, Johnson KC. Demographic and health factors associated with enrollment in posttrial studies: the Women's Health Initiative Hormone Therapy Trials. Clin Trials. 2013; 10(3):463-72.
Score: 0.010
-
Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE, Shumaker SA, Meyskens FL, Thompson IM. Health-related quality-of-life findings for the prostate cancer prevention trial. J Natl Cancer Inst. 2012 Sep 19; 104(18):1373-85.
Score: 0.010
-
Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt). 2010 Mar; 19(3):371-9.
Score: 0.008
-
Brunner RL, Cochrane B, Jackson RD, Larson J, Lewis C, Limacher M, Rosal M, Shumaker S, Wallace R. Calcium, vitamin D supplementation, and physical function in the Women's Health Initiative. J Am Diet Assoc. 2008 Sep; 108(9):1472-9.
Score: 0.007
-
Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, Patrick DL, Ware JE, Ganz PA, Shumaker SA, Lippman SM, Coltman CA. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Jul 04; 99(13):1025-35.
Score: 0.007
-
Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK, Shumaker SA. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006 May; 91(5):1802-10.
Score: 0.006
-
Wassertheil-Smoller S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B, Robbins J, Aragaki A, Dunbar-Jacob J. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med. 2004 Feb 09; 164(3):289-98.
Score: 0.005
-
Lindquist R, Dupuis G, Terrin ML, Hoogwerf B, Czajkowski S, Herd JA, Barton FB, Tracy MF, Hunninghake DB, Treat-Jacobson D, Shumaker S, Zyzanski S, Goldenberg I, Knatterud GL. Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study. Am Heart J. 2003 Dec; 146(6):1038-44.
Score: 0.005
-
Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003 Oct; 13(9 Suppl):S5-17.
Score: 0.005
-
Sherman AM, Shumaker SA, Kancler C, Zheng B, Reboussin DM, Legault C, Herrington DM. Baseline health-related quality of life in postmenopausal women with coronary heart disease: the Estrogen Replacement and Atherosclerosis (ERA) trial. J Womens Health (Larchmt). 2003 May; 12(4):351-62.
Score: 0.005
-
Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003 May 08; 348(19):1839-54.
Score: 0.005
-
Williams SW, Tell GS, Zheng B, Shumaker S, Rocco MV, Sevick MA. Correlates of sleep behavior among hemodialysis patients. The kidney outcomes prediction and evaluation (KOPE) study. Am J Nephrol. 2002 Jan-Feb; 22(1):18-28.
Score: 0.005